Metalloproteinase-9 contributes to inflammatory glia activation and nigro-striatal pathway degeneration in both mouse and monkey models of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism

Brain Structure and Function

Volumn 220, Issue 2, 2015, Pages 703-727

  Annese, V ^a,b   Herrero, María Trinidad ^b,d   Di Pentima, M ^a   Gomez, A ^b   Lombardi, L ^a   Ros, C M ^b,d   De Pablos, V ^b   Fernandez Villalba, E ^b   De Stefano, Maria Egle ^a,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF MURCIA   (Spain)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITAT JAUME I   (Spain)

Author keywords

Metalloproteinases; Neurodegeneration; Neuroinflammation; Parkinson s disease

Indexed keywords

GELATINASE B; MESSENGER RNA; NERVE PROTEIN; NEUN PROTEIN, MOUSE; NUCLEAR PROTEIN;

ANIMAL; C57BL MOUSE; CORPUS STRIATUM; ENCEPHALITIS; FEMALE; GENE INACTIVATION; GENETICS; MACACA FASCICULARIS; MALE; METABOLISM; MICROGLIA; MOUSE; NERVE CELL; NERVE TRACT; PARKINSONISM; PATHOLOGY; SPECIES DIFFERENCE; SUBSTANTIA NIGRA;

ANIMALS; CORPUS STRIATUM; ENCEPHALITIS; FEMALE; GENE KNOCKOUT TECHNIQUES; MACACA FASCICULARIS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICROGLIA; NERVE TISSUE PROTEINS; NEURAL PATHWAYS; NEURONS; NUCLEAR PROTEINS; PARKINSONIAN DISORDERS; RNA, MESSENGER; SPECIES SPECIFICITY; SUBSTANTIA NIGRA;

EID: 84946916611     PISSN: 18632653     EISSN: 18632661     Source Type: Journal    
DOI: 10.1007/s00429-014-0718-8     Document Type: Article

References (64)

1. Agrawal SM, Lau L, Yong VW (2008) MMPs in the central nervous system: where the good guys go bad. Semin Cell Dev Biol 19:42–51
2. Annese V, Barcia C, Ros-Bernal F, Gómez A, Ros CM, De Pablos V, Fernández-Villalba E, De Stefano ME, Herrero MT (2013) Evidence of oligodendrogliosis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism. Neuropathol Appl Neurobiol 39:132–143
3. Barcia C, Bautista V, Sánchez-Bahillo A, Fernández-Villalba E, Navarro-Ruis JM, Barreiro AF, Poza Y, Poza M, Herrero MT (2003) Circadian determinations of cortisol, prolactin and melatonin in chronic methyl-phenyl-tetrahydropyridine-treated monkeys. Neuroendocrinol 78:118–128
4. Barcia C, Sánchez-Bahillo A, Fernández-Villalba E, Bautista V, Poza Y, Poza M, Fernández-Barreiro A, Hirsch EC, Herrero MT (2004) Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 46:402–409
5. Barcia C, de Pablos V, Bautista-Hernández V, Sánchez-Bahillo A, Bernal I, Fernández-Villalba E, Martín J, Bañón R, Fernández-Barreiro A, Herrero MT (2005) Increased plasma levels of TNF-alpha but not of IL1-beta in MPTP-treated monkeys one year after the MPTP administration. Parkinsonism Relat Disord 11:435–439
6. Barcia C, Sanderson NSR, Barrett RJ, Wawrowsky K, Kroeger KM, Puntell M, Liu C, Castro MG, Lowenstein PR (2008) T cells’ immunological synapses induce polarization of brain astrocytes in vivo and in vitro: a novel astrocyte response mechanism to cellular injury. PLoS One 3:e2977
7. Barcia C, Ros CM, Annese V, Gómez A, Ros-Bernal F, Aguado-Yera D, Martínez-Pagán ME, de Pablos V, Fernandez-Villalba E, Herrero MT (2011) IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson’s disease. Cell Death Dis 2:e142
8. Barnum CJ, Tansey MG (2010) Modeling neuroinflammatory pathogenesis of Parkinson’s disease. Prog Brain Res 184:113–132
9. Bezard E, Dovero S, Imbert C, Boraud T, Gross CE (2000) Spontaneous long-term compensatory dopaminergic sprouting in MPTP-treated mice. Synapse 38:363–368
10. Braak H, Rüb U, Gai WP, Del Tredici K (2003) Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 110:517–536
11. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur N, Braak E (2006) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211
12. Braak H, Sastre M, Del Tredici K (2007) Development of α-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson’s disease. Acta Neuropathol 114:231–241
13. 4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119:182–192
14. Candelario-Jalil E, Yang Y, Rosenberg GA (2009) Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 158:983–994
15. Choi DH, Kim EM, Son HJ, Joh TH, Kim D, Beal MF, Hwang O (2008) A novel intracellular role of matrix metalloproteinase-3 during apoptosis of dopaminergic cells. J Neurochem 106:405–415
16. De Stefano ME, Annese V, Barcia C, Ros Bernal F, Fernandez-Villalba E, Herrero MT (2012) Neuroinflammation in Parkinson’s disease: a role for matrix metalloproteinases? In: Gemma C (ed) Neuroinflammation: pathogenesis, mechanisms and management. Nova Science Publishers Inc, Happauge
17. Del Signore A, De Sanctis V, Di Mauro E, Negri R, Perrone-Capano C, Paggi P (2006) Gene expression pathways induced by axotomy and decentralization of rat superior cervical ganglion neurons. Eur J Neurosci 23:65–74
18. Gerard M, Debyser Z, Desender L, Kahle PJ, Baert J, Baekelandt V, Engelborghs Y (2006) The aggregation of alpha-synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy. FASEB J 20:524–526
19. Goldschmidt T, Antel J, König FB, Brück W, Kuhlmann T (2009) Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 72:1914–1921
20. Herkenham M, Little MD, Bankiewicz K, Yang SC, Markey SP, Johannessen JN (1991) Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience 40:133–158
21. Herrero MT, Hirsch EC, Javoy-Agid F, Obeso JA, Agid Y (1993) Differential vulnerability to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of dopaminergic and cholinergic neurons in the monkey mesopontine tegmentum. Brain Res 624:281–285
22. Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol 8:382–397
23. Hirsh EC, Hunot S, Damier P, Faucheux B (1998) Glial cells and inflammation in Parkinson’s disease: a role in neurodegeneration? Ann Neurol 44:S115–S120
24. Houlden H, Singleton AB (2012) The genetics and neuropathology of Parkinson’s disease. Acta Neuropathol 124:325–338
25. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson’s disease. Neuroscience 72:355–363
26. Huntley GW (2012) Synaptic circuit remodelling by matrix metalloproteinases in health and disease. Nat Rev Neurosci 13:743–757
27. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S (1995) Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4:257–269
28. Kauppinen TM, Swanson RA (2005) Poly(ADP-ribose) polymerase-1 promotes microglial activation, proliferation, and matrix metalloproteinase-9-mediated neuron death. J Immunol 174:2288–2296
29. Kawasaki Y, Xu ZZ, Wang X, Park JY, Zhuang ZY, Tan PH, Gao YJ, Roy K, Corfas G, Lo EH, Ji RR (2008) Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med 14:331–336
30. Kim YS, Choi DH, Block ML, Lorenzl S, Yang L, Kim YJ, Sugama S, Cho BP, Hwang O, Browne SE, Kim SY, Hong J-S, Beal MF, Joh TH (2007) A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. FASEB J 21:179–180
31. Kim GW, Kim HJ, Cho KJ, Kim HW, Cho YJ, Lee BI (2009) The role of MMP-9 in integrin-mediated hippocampal cell death after pilocarpine-induced status epilepticus. Neurobiol Dis 36:169–180
32. Kim E-M, Shin E-J, Choi JH, Son HJ, Park I-S, Joh TH, Hwang O (2010) Matrix metalloproteinase-3 is increased and participates in neuronal apoptotic signaling downstream of caspase-12 during endoplasmic reticulum stress. J Biol Chem 285:16444–16452
33. Kim SK, Kang SW, Kim DH, Yun DH, Chung JH, Ban JY (2011) Matrix metalloproteinase-3 gene polymorphisms are associated with ischemic stroke. J Interferon Cytokine Res 32:81–86
34. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979–980
35. Larsen PH, Wells JE, Stallcup WB, Opdenakker G, Yong VW (2003) Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J Neurosci 23:11127–11135
36. Larsen PH, DaSilva AG, Conant K, Yong VW (2006) Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice. J Neurosci 26:2207–2214
37. Leonardo CC, Pennypacker KR (2009) Neuroinflammation and MMPs: potential therapeutic targets in neonatal hypoxic-ischemic injury. J Neuroinflammation 6:13
38. L’Episcopo F, Tirolo C, Caniglia S, Testa N, Serra PA, Impagnatiello F, Morale MC, Marchetti B (2010) Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. J Neuroinflammation 7:83
39. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Methods 25:402–408
40. Lorenzl S, Albers DS, Narr S, Chirichigno J, Beal MF (2002) Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson’s disease. Exp Neurol 178:13–20
41. Lorenzl S, Calingasan N, Yang L, Albers DS, Shugama S, Gregorio J, Krell HW, Chirichigno J, Joh T, Beal MF (2004) Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuromol Med 5:119–132
42. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38:1285–1291
43. Mounayar S, Boulet S, Tandé D, Jan C, Pessiglione M, Hirsch EC, Féger J, Savasta M, François C, Tremblay L (2007) A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. Brain 130:2898–2914
44. Nagatsu T, Mogi M, Ichinose H, Togari A (2000) Changes in cytokines and neurotrophins in Parkinson’s disease. Neural Transm Suppl 60:277–290
45. Oh LY, Larsen PH, Krekoski CA, Edwards DR, Donovan F, Werb Z, Yong VW (1999) Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. J Neurosci 19:8464–8475
46. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T (2005) Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 57:168–175
47. Ouchi Y, Yagi S, Yokokura M, Sakamoto M (2009) Neuroinflammation in the living brain of Parkinson’s disease. Parkinsonism Relat Disord Suppl 3:S200–S204
48. Page-McCaw A, Ewald AJ, Werb Z (2007) Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8:221–233
49. Parks WC, Wilson CL, Lopez-Boado YS (2004) Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4:617–629
50. Pott Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ (2008) Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson’s disease. Brain 131:1880–1894
51. Rolls A, Shechter R, Schwartz M (2009) The bright side of the glial scar in CNS repair. Nat Rev Neurosci 10:235–241
52. Sbai O, Ould-Yahoui A, Ferhat L, Gueye Y, Bernard A, Charrat E, Mehanna A, Risso JJ, Chauvin JP, Fenouillet E, Rivera S, Khrestchatisky M (2010) Differential vesicular distribution and trafficking of MMP-2, MMP-9, and their inhibitors in astrocytes. Glia 58:344–366
53. Streit WJ, Kreutzberg GW (1987) Lectin binding by resting and reactive microglia. J Neurocytol 16:249–260
54. Streit WJ, Walter SA, Pennell NA (1999) Reactive microgliosis. Progr Neurobiol 57:563–581
55. Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson’s disease: its role in neuronal death and implication for therapeutic intervention. Neurobiol Dis 37:510–518
56. Uhm JH, Dooley NP, Oh LY, Yong VW (1998) Oligodendrocytes utilize a matrix metalloproteinase, MMP-9, to extend processes along an astrocyte extracellular matrix. Glia 22:53–63
57. Walker EJ, Rosenberg GA (2010) Divergent role for MMP-2 in myelin breakdown and oligodendrocyte death following transient global ischemia. J Neurosci Res 88:764–773
58. Walsh S, Finn DP, Dowd E (2011) Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson’s disease in the rat. Neuroscience 175:251–261
59. Whitton PS (2010) Neuroinflammation and the prospects for anti-inflammatory treatment of Parkinson’s disease. Curr Opin Investig Drugs 11:788–794
60. Wilczynski GM, Konopacki FA, Wilczek E, Lasiecka Z, Gorlewicz A, Michaluk P, Wawrzyniak M, Malinowska M, Okulski P, Kolodziej LR, Konopka W, Duniec K, Mioduszewska B, Nikolaev E, Walczak A, Owczarek D, Gorecki DC, Zuschratter W, Ottersen OP, Kaczmarek L (2008) Important role of matrix metalloproteinase 9 in epileptogenesis. J Cell Biol 180:1021–1035
61. Woo MS, Park JS, Choi IY, Kim WK, Kim HS (2008) Inhibition of MMP-3 or -9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia. J Neurochem 106:770–780
62. Wright JW, Harding JW (2009) Contributions of matrix metalloproteinases to neural plasticity, habituation, associative learning and drug addiction. Neural Plast 2009:579382
63. Yong VW (2005) Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 6:931–944
64. Zhang H, Adwanikar H, Werb Z, Noble-Haeusslein LJ (2010) Matrix metalloproteinases and neurotrauma: evolving roles in injury and reparative processes. Neuroscientist 16:156–170